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ABSTRACT
Allergic bronchopulmonary aspergillosis is a lung disease occurring in patients with asthma or cystic fibrosis, triggered
by a hypersensitivity reaction to the presence of Aspergillus fumigatus in the airways. We report herein the case of a
patient presenting a clinical profile suggestive of asthma and meeting the clinical, laboratory testing and radiological
criteria for a diagnosis of allergic bronchopulmonary aspergillosis. The importance of such findings is that early
diagnosis can reduce the risk of respiratory exacerbations and fibrosis.
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INTRODUCTION
Allergic bronchopulmonary aspergillosis (ABPA)
is a lung disease occurring in patients with asthma
or cystic fibrosis, caused by an allergic response to
multiple antigens expressed by the Aspergillus
fumigatus that colonizes the bronchial mucus.(1)
Some authors prefer the term allergic
bronchopulmonary mycosis, considering that, in
addition to A. fumigatus, other fungi, such as A. flavus,
Candida spp., Penicillium spp., Curvularia spp. and
Drechslera spp., can colonize the bronchi and
produce a similar immune response.(1)
Recurrent episodes of bronchial obstruction,
inflammation and mucoid impaction are characteristic
of ABPA, which, if not diagnosed early and treated
correctly, can also result in bronchiectasis, fibrosis
and irreversible respiratory conditions.(2)
Currently, ABPA is more frequently diagnosed
than it was in the past. It is estimated that ABPA is
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present in 2% to 28% of patients with asthma and
in 2% to 15% of patients with cystic fibrosis. The
28% and 15% frequencies represent diagnoses made
by pulmonologists and allergists, whereas the 2%
frequencies represent diagnoses made by general
clinicians. This wide range in the diagnosis frequency
suggests that pulmonologists and allergists, based
on their knowledge of ABPA, investigate and diagnose
it more frequently than do general clinicians.(1)
In the present study, we report a case that
presented interesting findings in terms of the
clinical history, chest X-rays, and laboratory tests,
emphasizing the importance of ABPA detection in
patients with asthma. In asthma patients diagnosed
with ABPA, the treatment differs from that
indicated for patients with asthma only. Therefore,
early diagnosis of ABPA can improve the prognosis.
CASE REPORT
A 42-year-old female architect reported having
had a cough for ten years. The cough had begun
when she was on holiday at a beach house, where
she noticed a strong mold smell. Since than, she
had been experiencing fits of coughing, either dry
cough or cough producing dense, greenish sputum.
In addition to the mold, the patient mentioned other
factors, such as dust, cold weather, and laughing,
that would trigger her coughing fits. She reported
that, during this ten-year period, she did not have
Figure 1 - Chest X-ray with glove-finger shadow (arrow) and
nodular opacities in the right middle third
any episodes of fever, chest pain or dyspnea, but
she occasionally presented wheezing, and she had
once produced bloody sputum.
The patient had a family history of asthma, allergic
rhinitis, and emphysema. She also had a personal
history of allergic rhinitis (during adolescence).
The clinical examination revealed rhonchi and
wheezing, both of which were bilateral and diffuse.
Additional examinations showed the following:
normal spirometry results, positivity for A.
fumigatus in immediate cutaneous reaction allergy
testing (skin prick test); eosinophilia (13%) in the
blood workup; total serum IgE levels higher than
1000 ng/ml; and radioallergosorbent test (RAST)
class 3 in the determination of specific IgE for A.
fumigatus. On the chest X-ray, glove-finger shadows
were observed in the right superior third (Figure 1).
The high-resolution computed tomography scan
revealed central bronchiectasis (Figure 2).
Figure 2 - High-resolution computed tomography of the
chest demonstrating central bronchiectasis and bilateral
signet-ring sign
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The criteria for a diagnosis of ABPA are as
follows: asthma; eosinophilia; opacities in the lung;
central bronchiectasis accompanied by IgE > 1000
ng/ml; positive skin prick test; and class 3 RAST
positivity for A. fumigatus.
Having met these criteria, the patient was
treated with 50 mg/day of prednisone for four
weeks, and two inhalations of salbutamol spray
totaling 100 µg every six hours. The prednisone
dose was gradually decreased on a weekly basis
over the eight weeks that followed.
By the end of the treatment, the coughing,
expectoration, and wheezing, as well as the amount
of mold eliminated from the bronchi, had been
reduced. In addition, the pulmonary auscultation
findings were normal, the RAST result for A. fumigatus
was class 2, the degree of eosinophilia decreased (to
4%), and total serum IgE was 608 ng/ml.
DISCUSSION
The diagnosis of ABPA is based on clinical,
radiographic, and immunologic criteria: history of
asthma (84% to 96%)(3-4); positive skin prick test
for A. fumigatus antigens; presence of precipitins
against A. fumigatus (RAST positivity for A.
fumigatus); serum IgE > 1000 ng/ml; eosinophilia
in peripheral blood > 500 mm3 (8% to 40%)(3);
pulmonary infiltrate; central bronchiectasis; and
increase in specific plasma IgE and IgG for A.
fumigatus.(5) If the first three of these criteria are
met, but there is no bronchiectasis, the patient is
classified as having serologic ABPA. If there is
central bronchiectasis accompanied by at least
three other criteria (such as history of asthma,
positive skin prick test for A. fumigatus antigens,
and increase in serum IgE), the patient is classified
as having central bronchiectasis ABPA.(5)
In the case reported, the patient met all of the
criteria for central bronchiectasis ABPA, as well as
meeting one more established criteria: RAST
positivity for A. fumigatus. Despite the fact that
the spirometry results revealed a normal pattern, a
diagnosis of asthma was made based on the clinical
symptom of cough triggered by dust, mold, cold
weather, and exertion, as well as that of wheezing,
together with a personal history of allergic rhinitis
and a family history of rhinitis/asthma.
In addition, the clinical findings of cough
productive of dense, greenish sputum (containing
bronchial mold) and hemoptysis confirm the
superimposition of asthma symptoms complicated
by ABPA.(6)
Performing a skin prick test for A. fumigatus
should be the first step in the evaluation of an
individual with asthma in order to diagnose ABPA,
since a negative result on this test and a
subsequent negative intradermal reaction for A.
fumigatus virtually rule out the hypothesis of
ABPA.(1) Since the skin prick test was positive in
this case, we analyzed total serum IgE and found
it to be higher than 1000 ng/ml. We also performed
a RAST for specific precipitins against A. fumigatus
antigens, and the result was positive. Based on
these data, the diagnosis of ABPA was confirmed.
In various studies, the changes observed on
the chest X-rays of patients with ABPA have been
described as extensive consolidations and alveolar
infiltrate, predominantly occurring in the superior
lobes, together with mucoid impaction in the
central bronchus. The findings known as the glove-
finger shadow and the toothpaste shadow are
transitory images of mucoid impaction, which can
disappear with cough or after corticosteroid
administration.(7-9) On the chest X-ray, opaque
shadows in glove-finger form were observed in the
upper third of the right hemithorax (Figure 1). On
the high-resolution computed tomography scan, there
were signs of central bronchiectasis (Figure 2).
According to the literature, glove-finger shadows
are suggestive of ABPA,(10) reflecting inflammation,
thickening, and dilation of the bronchial tree
caused by the mucoid impaction in the airways.(11)
In order to , It has been suggested that high-resolution
computed tomography is the best diagnostic
technique for detecting central bronchiectasis, for
which chest X-ray is neither sensitive nor specific.(4)
The treatment was based on the control of acute
inflammation episodes, in order to avoid the
progression of pulmonary damage.(6) To that end,
it is recommended that oral prednisone be given
at 0.5 mg/kg/day for 14 days, followed by 0.5 mg/
kg/day every other day, and that the dose be
tapered for the next three to six months.(12) Inhaled
steroids can also aid in the control of asthma
symptoms. However, there is no proof of their
eff icacy in prevent ing episodes of ABPA
exacerbation.(6)
For patients who do not present clinical
improvement after treatment with 0.5 mg/kg/day
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of an oral corticosteroid for a period of at least 30
days, as well as for those who require high doses
of oral corticosteroid to improve the symptoms,
we can combine an oral corticosteroid with 100
mg/day of itraconazole in order to decrease the
corticosteroid dose, since itraconazole has a
corticosteroid-sparing effect, leading to control of
the disease. A large randomized, double-blind
study compared itraconazole with placebo in 55
patients who were already being treated with a
corticosteroid. The addition of itraconazole for 16
weeks was associated with a significant increase
in patient clinical response. However, further studies
are needed in order to confirm these findings, since
the level of evidence in that study was category B.
It would be prudent to assert that itraconazole
should not be used in place of a corticosteroid in
the treatment of ABPA. However, the use of
itraconazole can be considered for patients that
require prolonged treatment with high doses of a
corticosteroid.(13)
Based on the clinical and radiological criteria,
ABPA can be classified as follows: stage I
(exacerbation); stage II (remission: absence of
pulmonary radiographic alterations and respiratory
symptoms, without relapse for at least six months,
and a 50% to 75% decrease in total serum IgE)(14);
stage III (recurrent exacerbations); stage IV
(corticosteroid-dependent); and stage V (fibrotic
lung disease).(3) After treatment with a corticosteroid,
the patient presented remission (stage II), with a
reduction in the respiratory symptoms and a drop
in total serum IgE (to 608 ng/ml).
The importance of a patient achieving
remission is that it prevents the progression to the
more severe stages of the disease. According to
one study,(14) mortality in stage V can reach 100%.
According to some authors, serologic ABPA can
represent a initial stage of the disease.(15) Therefore,
it should be diagnosed and treated early, even
before it develops to central bronchiectasis ABPA,
in order to reduce the chance of anatomical and
functional pulmonary damage.(16) Therefore, ABPA
should be suspected and investigated in all patients
with asthma who do not present clinical and
functional improvement after being treated as
usual, as well as in those with asthma accompanied
by wheezing and presenting radiographic
alterations not consistent with asthma.(14)
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